Department of Chemistry and Biochemistry, University of Maryland, College Park, Maryland 20742, United States.
Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, New York 10065, United States.
Bioconjug Chem. 2021 Aug 18;32(8):1888-1897. doi: 10.1021/acs.bioconjchem.1c00314. Epub 2021 Aug 5.
Antibody-drug conjugates (ADCs) are an important class of therapeutic agents that harness the highly specific antigen targeting property of antibodies to deliver toxic drugs for targeted cell killing. Site-specific conjugation methods are highly desirable for constructing homogeneous ADCs that possess a well-defined antibody-to-drug ratio, stability, ideal pharmacological profile, and optimal therapeutic index. We report here a facile synthesis of functionalized glycan oxazolines from free sialoglycans that are key donor substrates for enzymatic Fc glycan remodeling and the application of an efficient endoglycosidase mutant (Endo-S2 D184M) for site-specific glycan transfer to construct homogeneous ADCs. We found that by a sequential use of two coupling reagents under optimized conditions, free sialoglycans could be efficiently converted to selectively functionalized glycan oxazolines carrying azide-, cyclopropene-, and norbornene-tags, respectively, in excellent yield and in a simple one-pot manner. We further demonstrated that the recently reported Endo-S2 D184 M mutant was highly efficient for Fc glycan remodeling with the selectively modified glycan oxazolines to introduce tags into an antibody, which required a significantly smaller amount of glycan oxazolines and a much shorter reaction time than that of the Endo-S D233Q-catalyzed reaction, thus minimizing the side reactions. Finally homogeneous ADCs were constructed with three different click reactions. The resulting ADCs showed excellent serum stability, and cytotoxicity assays indicated that all the three ADCs generated from the distinct click reactions possessed potent and comparable cytotoxicity for targeted cancer cell killing.
抗体药物偶联物(ADCs)是一类重要的治疗剂,利用抗体对特定抗原的高度靶向特性,将毒性药物递送至靶细胞进行杀伤。构建具有均一性、明确的抗体药物比、稳定性、理想的药代动力学特征和最佳治疗指数的 ADC,需要使用定点偶联方法。我们在此报告了一种从游离唾液酸聚糖出发,通过简便的方法合成功能性聚糖恶唑啉的方法,这些聚糖是酶促 Fc 聚糖重塑的关键供体底物,并且还应用了高效的内切糖苷酶突变体(Endo-S2 D184M),用于定点聚糖转移以构建均一性 ADC。我们发现,通过在优化条件下使用两种偶联试剂的顺序使用,可以有效地将游离唾液酸聚糖转化为分别带有叠氮基、环丙烷基和降冰片烯基的选择性功能化聚糖恶唑啉,产率优异,且在简单的一锅法中进行。我们进一步证明,最近报道的 Endo-S2 D184M 突变体对于用选择性修饰的聚糖恶唑啉进行 Fc 聚糖重塑非常有效,可以将标签引入抗体中,这需要比 Endo-S D233Q 催化的反应少得多的聚糖恶唑啉和更短的反应时间,从而最小化副反应。最后,通过三种不同的点击反应构建了均一性 ADC。所得 ADC 表现出优异的血清稳定性,细胞毒性测定表明,通过三种不同的点击反应生成的三种 ADC 对靶向癌细胞杀伤均具有强大且相当的细胞毒性。